CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives
- Canurta
- Jun 6
- 2 min read
CNR-401 Progresses Toward Clinical-Stage Milestones
New preclinical studies are underway to evaluate CNR-401’s neuroprotective potential across ALS and other neurodegenerative diseases. Early-stage work now includes a Drosophila melanogaster (fruit fly) ALS model and blood-brain barrier permeability testing in mice, two key components of Canurta’s translational strategy. These efforts strengthen our scientific foundation as we move closer to initiating clinical trials.
Capital Raise: Supporting the Next Phase of Growth
With clinical preparations advancing, Canurta is actively raising capital to support the development of CNR-401 and our broader portfolio. This funding will fuel IND-enabling studies, expand research collaborations, and scale our AI-integrated platform for botanical drug development.
CNR-301 Showcased at MedCity INVEST Pitch Perfect
On May 20, Canurta was selected as a finalist in the Biopharma Track at MedCity INVEST 2025 in Chicago, where we presented CNR-301, our preclinical antifungal and anti-inflammatory asset. The pitch highlighted CNR-301’s synergy against antimicrobial resistance and was well received by investors and industry leaders. This recognition reflects the growing interest in novel polyphenol therapeutics to address urgent global health challenges.
Base Batch Submission: Accelerating Open Innovation
As part of the global Base Batch Buildathon, Canurta submitted PolyKye Onchain, a decentralized platform designed to unlock collaborative drug discovery.
PolyKye Onchain addresses a major challenge in life sciences: drug discovery remains siloed, slow, and costly. Our approach uses blockchain to record research progress transparently and integrates AI tools that make early-stage discovery accessible to a global community of scientists and innovators.
By open-sourcing aspects of our bioinformatics infrastructure, we aim to accelerate progress on hard-to-treat conditions, reduce duplication of effort, and bring more equity to the discovery pipeline. Participation in this global buildathon also strengthens Canurta’s technical capacity, expands its innovation network, and furthers our mission to democratize science.
CDL Neuro 2024/25 Graduation
Following months of collaboration with mentors in life sciences and market development, Canurta has officially completed the Creative Destruction Lab (CDL) Neuro stream. The experience sharpened our operational focus and refined our investor-facing strategies. We’re grateful to the CDL network for their continued support.
Perplexity for Startups Acceptance
Canurta has been accepted into the Perplexity for Startups program, gaining access to Perplexity Enterprise Pro and API capabilities. These tools are now helping to enhance our internal bioinformatics workflows and accelerate preclinical research. We extend appreciation to CDL-Toronto for supporting this milestone.
The Healing Project: A Story-Driven Gateway to Scientific Engagement
Progress continues toward the closed beta launch of The Healing Project (THP), our digital companion app designed to bring Canurta’s research to life through interactive storytelling and AI chat features.
